Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Apr, 4 2026
Feb, 2 2024
Aug, 27 2026
Dec, 25 2025
May, 13 2026